Analysts Issue Forecasts for Metagenomi FY2025 Earnings

Metagenomi, Inc. (NASDAQ:MGX) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share estimates for Metagenomi in a research report issued on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings per share of ($1.47) for the year. The consensus estimate for Metagenomi’s current full-year earnings is ($2.46) per share. Chardan Capital also issued estimates for Metagenomi’s FY2026 earnings at ($0.76) EPS.

Metagenomi (NASDAQ:MGX) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). The business had revenue of $9.61 million during the quarter, compared to the consensus estimate of $13.18 million. Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. During the same quarter last year, the company earned ($20.05) EPS.

A number of other research analysts have also recently weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 18th. HC Wainwright upped their price objective on Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.40.

Metagenomi Stock Performance

MGX opened at $1.59 on Thursday. Metagenomi has a fifty-two week low of $1.56 and a fifty-two week high of $11.80. The firm has a 50-day moving average of $2.30 and a 200 day moving average of $2.45. The firm has a market cap of $59.44 million and a P/E ratio of -0.61.

Hedge Funds Weigh In On Metagenomi

Several large investors have recently modified their holdings of MGX. Geode Capital Management LLC boosted its holdings in Metagenomi by 73.8% in the 4th quarter. Geode Capital Management LLC now owns 587,421 shares of the company’s stock worth $2,121,000 after buying an additional 249,390 shares during the period. Norges Bank purchased a new stake in shares of Metagenomi during the fourth quarter worth $1,300,000. Peapod Lane Capital LLC purchased a new position in shares of Metagenomi in the fourth quarter valued at $1,268,000. Northern Trust Corp raised its stake in shares of Metagenomi by 185.6% during the 4th quarter. Northern Trust Corp now owns 223,934 shares of the company’s stock valued at $808,000 after purchasing an additional 145,536 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Metagenomi by 209.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after purchasing an additional 92,468 shares in the last quarter.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.